Hanger, Inc. HNGR
We take great care to ensure that the data presented and summarized in this overview for HANGER, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in HNGR
Top Purchases
Top Sells
About HNGR
Hanger, Inc. provides orthotic and prosthetic (O&P) services in the United States. It operates in two segments, Patient Care and Products & Services. The Patient Care segment owns and operates Hanger clinic, which specializes in the design, fabrication, and delivery of custom O&P devices through patient care clinics and satellite locations; and offers payor network contracting services to other O&P providers. The Products & Services segment engages in the distribution of various O&P parts, componentry, and devices to independent O&P providers; development of specialized rehabilitation technologies; and provision of evidence-based clinical programs for post-acute rehabilitation to patients at approximately 4,000 skilled nursing and post-acute providers. This segment also manufactures and sells therapeutic footwear for diabetic patients in the podiatric market. As of December 31, 2021, the company operated approximately 760 patient care clinics and 115 satellite locations in 47 states and the District of Columbia. It also distributes O&P devices and components, manages O&P networks, and provides therapeutic solutions to patients and businesses in acute, post-acute, and clinic settings. The company was formerly known as Hanger Orthopedic Group, Inc. and changed its name to Hanger, Inc. in June 2012. Hanger, Inc. was founded in 1861 and is headquartered in Austin, Texas.
Insider Transactions at HNGR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 03
2022
|
Kathryn M Sullivan Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
62,026
-100.0%
|
$1,116,468
$18.75 P/Share
|
Oct 03
2022
|
Richard Pettingill Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
78,135
-100.0%
|
$1,406,430
$18.75 P/Share
|
Oct 03
2022
|
Cynthia L Lucchese Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
67,851
-100.0%
|
$1,221,318
$18.75 P/Share
|
Oct 03
2022
|
Mark M Jones Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,594
-100.0%
|
$370,692
$18.75 P/Share
|
Oct 03
2022
|
Stephen E Hare Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
107,009
-100.0%
|
$1,926,162
$18.75 P/Share
|
Oct 03
2022
|
Thomas E Hartman SVP and General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
153,580
-100.0%
|
$2,764,440
$18.75 P/Share
|
Oct 03
2022
|
Keri Jolly SVP & Chief HR Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
44,411
-100.0%
|
$799,398
$18.75 P/Share
|
Oct 03
2022
|
Thomas E Kiraly EVP & Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
276,451
-100.0%
|
$4,976,118
$18.75 P/Share
|
Oct 03
2022
|
Kathleen L Means Chief Supply Chain Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,760
-100.0%
|
$103,680
$18.75 P/Share
|
Oct 03
2022
|
Michael H Oros President, Hanger Clinic |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,889
-100.0%
|
$304,002
$18.75 P/Share
|
Oct 03
2022
|
Scott Ranson EVP, Chief Info Officer * |
SELL
Sale (or disposition) back to the issuer
|
Direct |
117,479
-100.0%
|
$2,114,622
$18.75 P/Share
|
Oct 03
2022
|
Peter A Stoy EVP & Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
65,190
-100.0%
|
$1,173,420
$18.75 P/Share
|
Oct 03
2022
|
John T Fox Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
43,561
-100.0%
|
$784,098
$18.75 P/Share
|
Oct 03
2022
|
Thomas C Freyman Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
43,561
-100.0%
|
$784,098
$18.75 P/Share
|
Oct 03
2022
|
Mitchell D Dobson SVP, Chief Compliance Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
42,840
-100.0%
|
$771,120
$18.75 P/Share
|
Oct 03
2022
|
James H Campbell SVP, Chief Clinical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
52,391
-100.0%
|
$943,038
$18.75 P/Share
|
Oct 03
2022
|
Christopher B Begley Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
76,414
-100.0%
|
$1,375,452
$18.75 P/Share
|
Oct 03
2022
|
Asif Ahmad Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
70,837
-100.0%
|
$1,275,066
$18.75 P/Share
|
Oct 03
2022
|
Gabrielle B. Adams Vice President Accounting |
SELL
Sale (or disposition) back to the issuer
|
Direct |
68,930
-100.0%
|
$1,240,740
$18.75 P/Share
|
Oct 03
2022
|
Gabrielle B. Adams Vice President Accounting |
SELL
Bona fide gift
|
Direct |
2,442
-4.05%
|
-
|